Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis.

Ylikorkala O, Nilsson CG, Hirvonen E, Viinikka L

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology1 Dec 1990Cited by 11 (Europe PMC)

PMID2150580DOI10.3109/09513599009024979PepBankPUB-02150580

Publisher page PubMedAsk about this study

Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanNon-randomized trialSafety outcome
In women with endometriosis, nafarelin reduced estradiol to less than 21.6 pg/ml after 3 months, as did danazol.
In plain wordsIn women with endometriosis, estradiol fell during nafarelin and danazol treatment.
Peptide
Nafarelin
Outcome
DecreaseHypoestrogenism
Study
n = 12
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
400 micrograms daily · intranasal · 3 monthsAs given in this study (human).
Measurements
Estradiol (E2)
< 21.6 pg/ml
after 3 months, nafarelin and danazol groups
Source sentences
Summary
Both treatments had already led to hypoestrogenism (E2 less than 21.6 pg/ml) after 3 months.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058001
02HumanNon-randomized trialSafety outcome
In women with endometriosis, urinary hydroxyproline rose approximately 50% during nafarelin treatment, as during danazol treatment.
In plain wordsIn women with endometriosis, a bone breakdown marker rose during nafarelin and danazol treatment.
Peptide
Nafarelin
Outcome
IncreaseUrinary hydroxyproline at 6 months
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Measurements
Rise in 24-h urinary hydroxyproline output
≈ 50%
6 months, nafarelin and danazol groups
Source sentences
Summary
They both were accompanied by an approximately 50% rise in 24-h urinary hydroxyproline output, suggesting accelerated bone resorption at 6 months
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058002
03HumanNon-randomized trialSafety outcome
In women with endometriosis, urinary calcium did not change significantly during nafarelin treatment.
In plain wordsIn women with endometriosis, urinary calcium did not change significantly during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeUrinary calcium
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
They both were accompanied by an approximately 50% rise in 24-h urinary hydroxyproline output, suggesting accelerated bone resorption at 6 months; yet urinary calcium output did not change significantly.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058003
04HumanNon-randomized trialSafety outcome
In women with endometriosis, serum osteocalcin rose by 80-120% during nafarelin and danazol treatment.
In plain wordsIn women with endometriosis, a bone formation marker increased during nafarelin and danazol treatment.
Peptide
Nafarelin
Outcome
IncreaseSerum osteocalcin
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Measurements
Rise in serum osteocalcin
80 to 120%
6 months, nafarelin and danazol groups
Source sentences
Summary
Serum osteocalcin rose by 80-120% and bone alkaline phosphatase activity by 34-40%, suggesting stimulated bone formation at the same time.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058004
05HumanNon-randomized trialSafety outcome
In women with endometriosis, bone alkaline phosphatase rose by 34-40% during nafarelin and danazol treatment.
In plain wordsIn women with endometriosis, bone alkaline phosphatase increased during nafarelin and danazol treatment.
Peptide
Nafarelin
Outcome
IncreaseBone alkaline phosphatase
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Measurements
Rise in bone alkaline phosphatase activity
34 to 40%
6 months, nafarelin and danazol groups
Source sentences
Summary
Serum osteocalcin rose by 80-120% and bone alkaline phosphatase activity by 34-40%, suggesting stimulated bone formation at the same time.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058005
06HumanNon-randomized trialSafety outcome
In women with endometriosis, distal radius cortical bone mineral content did not change detectably during nafarelin treatment.
In plain wordsIn women with endometriosis, forearm cortical bone mineral content did not change detectably during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeDistal radius cortical mineral content
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
No detectable changes ensued in cortical bone mineral content in the distal radius or in serum levels of calcium, calcitonin, parathyroid hormone, or aminoterminal propeptide of type III collagen.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058006
07HumanNon-randomized trialSafety outcome
In women with endometriosis, serum calcium did not change detectably during nafarelin treatment.
In plain wordsIn women with endometriosis, blood calcium did not change detectably during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeSerum calcium
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
No detectable changes ensued in cortical bone mineral content in the distal radius or in serum levels of calcium, calcitonin, parathyroid hormone, or aminoterminal propeptide of type III collagen.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058007
08HumanNon-randomized trialSafety outcome
In women with endometriosis, serum calcitonin did not change detectably during nafarelin treatment.
In plain wordsIn women with endometriosis, calcitonin did not change detectably during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeSerum calcitonin
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
No detectable changes ensued in cortical bone mineral content in the distal radius or in serum levels of calcium, calcitonin, parathyroid hormone, or aminoterminal propeptide of type III collagen.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058008
09HumanNon-randomized trialSafety outcome
In women with endometriosis, serum parathyroid hormone did not change detectably during nafarelin treatment.
In plain wordsIn women with endometriosis, parathyroid hormone did not change detectably during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeSerum parathyroid hormone
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
No detectable changes ensued in cortical bone mineral content in the distal radius or in serum levels of calcium, calcitonin, parathyroid hormone, or aminoterminal propeptide of type III collagen.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058009
10HumanNon-randomized trialSafety outcome
In women with endometriosis, serum aminoterminal propeptide of type III collagen did not change detectably during nafarelin treatment.
In plain wordsIn women with endometriosis, a collagen marker did not change detectably during nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeType III collagen propeptide
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
No detectable changes ensued in cortical bone mineral content in the distal radius or in serum levels of calcium, calcitonin, parathyroid hormone, or aminoterminal propeptide of type III collagen.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058010
11HumanNon-randomized trialSafety outcome
In women with endometriosis, hydroxyproline output remained elevated three months after nafarelin treatment.
In plain wordsIn women with endometriosis, a bone breakdown marker remained elevated three months after nafarelin treatment.
Peptide
Nafarelin
Outcome
IncreaseHydroxyproline after withdrawal
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Three months after treatment, hydroxyproline output, serum osteocalcin and bone alkaline phosphatase were still elevated in women taking nafarelin, whereas only serum osteocalcin was elevated in women taking danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058011
12HumanNon-randomized trialSafety outcome
In women with endometriosis, serum osteocalcin remained elevated three months after nafarelin treatment.
In plain wordsIn women with endometriosis, osteocalcin remained elevated three months after nafarelin treatment.
Peptide
Nafarelin
Outcome
IncreaseOsteocalcin after withdrawal
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Three months after treatment, hydroxyproline output, serum osteocalcin and bone alkaline phosphatase were still elevated in women taking nafarelin, whereas only serum osteocalcin was elevated in women taking danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058012
13HumanNon-randomized trialSafety outcome
In women with endometriosis, bone alkaline phosphatase remained elevated three months after nafarelin treatment.
In plain wordsIn women with endometriosis, bone alkaline phosphatase remained elevated three months after nafarelin treatment.
Peptide
Nafarelin
Outcome
IncreaseBone alkaline phosphatase after withdrawal
Study
n = 12
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Three months after treatment, hydroxyproline output, serum osteocalcin and bone alkaline phosphatase were still elevated in women taking nafarelin, whereas only serum osteocalcin was elevated in women taking danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve patients with laparoscopically confirmed endometriosis received nafarelin (400 micrograms day intranasally) and six patients danazol (600 mg day orally) for 6 months.
Report a problemFND-0215058013

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.